Karyopharm Therapeutics Inc. KPTI
0.09 USD -0.02 (-21.16%)
At closeNov 3, 2026, 7:59 PM EST
0.09 0.00 +0.23%
After hours · Nov 3, 7:59 PM ET
0.0821 Day range 0.11
0.0821 52-week range 10.99
- YTD
- -98.80%
- 1 year
- -98.55%
News
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Nordicus Partners (NASDAQ:NORD) stock increased by 10.8% to $4.5 during Tuesday's after-market session. The market value of their outstanding shares is at $71.5 million. Gelteq (NASDAQ:GELS)…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Curis (NASDAQ:CRIS) stock increased by 25.6% to $0.83 during Tuesday's regular session. The company's market cap stands at $1.6 million. Pasithea Therapeutics (NASDAQ:KTTA) shares increased…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Dyadic International (NASDAQ:DYAI) stock rose 13.4% to $0.43 during Tuesday's pre-market session. The market value of their outstanding shares is at $15.0 million. Aethlon Medical…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Inovio Pharmaceuticals (NASDAQ:INO) shares rose 211.2% to $1.88 during Monday's regular session. The company's market cap stands at $62.2 million. BeyondSpring (NASDAQ:BYSI) stock moved…
benzinga.com Crude Oil Tumbles 7%; ISM Manufacturing PMI Rises In October U.S. stocks climbed as manufacturing data beat estimates; consumer shares surged, oil fell 7%, and Inovio, Perion and Evgo rallied.
benzinga.com Dow Jumps Over 400 Points; Marriott Posts Upbeat Q3 Earnings U.S. stocks rose Monday, led by a 400-point Dow gain. Marriott beat estimates; Inovio surged 195%, while oil fell 6% and Karyopharm sank 79%.
benzinga.com Karyopharm Therapeutics Enters Restructuring Agreement With Lenders, Clearing Path For A Merger With Ayrmid; Secures Commitments For Up To $55M Of Debtor-In-Possession Financing During this process, Karyopharm remains focused on its commitment to advancing its multiple myeloma and myelofibrosis programs and improving the lives of the patients Karyopharm serves and will…
prnewswire.com Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the Future – The Company Remains Focused on Supporting Patients and Advancing its Programs in Multiple Myeloma and Myelofibrosis – – Ayrmid will Serve as Lead Bidder in Court-Supervised Sale Process to Maximize…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Neumora Therapeutics (NASDAQ:NMRA) shares rose 11.9% to $0.41 during Tuesday's after-market session. The market value of their outstanding shares is at $73.8 million. Pulmonx (NASDAQ:LUNG)…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Pomdoctor (NASDAQ:POM) shares rose 25.6% to $1.47 during Friday's after-market session. The market value of their outstanding shares is at $8.3 million. GeneDx Holdings (NASDAQ:WGS) shares…
benzinga.com Karyopharm Therapeutics Extends Forbearance Period End Date To November 1, 2026 As previously disclosed in the Current Reports on Form 8-K filed by Karyopharm Therapeutics Inc. (the "Company") on September 11, 2026 and October 14, 2026, the Company entered into a Forbearance…- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Profusa (NASDAQ:PFSA) shares moved upwards by 35.4% to $1.15 during Thursday's regular session. Karyopharm Therapeutics (NASDAQ:KPTI) shares increased by 29.12% to $0.55. The company's market…
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Vivos Therapeutics (NASDAQ:VVOS) stock increased by 17.9% to $0.16 during Monday's after-market session. The market value of their outstanding shares is at $2.8 million. SCWorx (NASDAQ:WORX)…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers MaxCyte (NASDAQ:MXCT) shares rose 34.5% to $1.3 during Wednesday's regular session. The company's market cap stands at $102.6 million. Liquidia (NASDAQ:LQDA) stock moved upwards by 26.29% to…
benzinga.com Karyopharm Therapeutics Extends Forbearance Period To October 15 As previously disclosed in the Current Report on Form 8-K filed by Karyopharm Therapeutics Inc. (the "Company") on September 11, 2026, the Company entered into a Forbearance Agreement and Limited…- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers HeartBeam (NASDAQ:BEAT) stock moved upwards by 70.5% to $0.74 during Monday's regular session. The market value of their outstanding shares is at $24.4 million. PDS Biotechnology…
prnewswire.com Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) NEWTON, Mass., Oct. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company…
defenseworld.net Reviewing Alpha Cognition (NASDAQ:ACOG) & Karyopharm Therapeutics (NASDAQ:KPTI) Karyopharm Therapeutics (NASDAQ: KPTI - Get Free Report) and Alpha Cognition (NASDAQ: ACOG - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will…- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Tenon Medical (NASDAQ:TNON) shares moved upwards by 49.2% to $7.91 during Friday's pre-market session. The company's market cap stands at $3.5 million. Biodexa Pharmaceuticals (NASDAQ:BDRX)…
prnewswire.com Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEWTON, Mass., Sept. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company…
gurufocus.com Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIOÂ (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis
benzinga.com Karyopharm Therapeutics Submits sNDA To FDA Seeking Accelerated Approval For XPOVIO In Combination With Ruxolitinib For Patients With Myelofibrosis – sNDA Submitted under the Accelerated Approval Pathway; Priority Review Requested –NEWTON, Mass., Aug. 31, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage…
prnewswire.com Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis – sNDA Submitted under the Accelerated Approval Pathway; Priority Review Requested – NEWTON, Mass., Aug. 31, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ: KPTI). Such investors are…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI). Such investors…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI NEW YORK, Aug. 20, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ: KPTI). Such investors are…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI NEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI). Such investors…
seekingalpha.com Karyopharm Therapeutics Inc. (KPTI) Q2 2026 Earnings Call Transcript Karyopharm Therapeutics Inc. (KPTI) Q2 2026 Earnings Call Transcript
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ: KPTI). Such investors are…
zacks.com Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $2.32 per share versus the Zacks Consensus Estimate of a loss of $1.53. This compares to a loss of $4.32 per share a year ago.- benzinga.com Karyopharm Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript Karyopharm Therapeutics (NASDAQ:KPTI) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is…
benzinga.com Karyopharm Therapeutics Affirms FY2026 Sales Guidance of $130.000M-$150.000M vs $133.736M Est Karyopharm Therapeutics (NASDAQ:KPTI) affirms FY2026 sales outlook from $130.000 million-$150.000 million to $130.000 million-$150.000 million vs $133.736 million estimate.
prnewswire.com Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission – Planned August sNDA Submission for Selinexor in Combination with Ruxolitinib in Myelofibrosis under the Accelerated Approval Pathway Remains on Track – – Planned sNDA for Selinexor plus Ruxolitinib…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI). Such investors…
prnewswire.com Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026 -- Conference Call Scheduled for Thursday, August 13, 2026, at 8:00 a.m. ET -- NEWTON, Mass.
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ: KPTI). Such investors are…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI). Such investors…
prnewswire.com Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) NEWTON, Mass., Aug. 3, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company…- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular session. SCYNEXIS (NASDAQ:SCYX) stock moved upwards by 22.54% to $4.57. The market value of their outstanding…
benzinga.com Crude Oil Gains 1%; Apple Shares Tumble After Q3 Results Dow up 0.38%, NASDAQ up 0.25%, S&P 500 up 0.22%. Consumer discretionary shares up 5.6%, materials stocks down 2.7%. Apple beats estimates, shares down 9%.- benzinga.com Piper Sandler Maintains Overweight on Karyopharm Therapeutics, Lowers Price Target to $7 Piper Sandler analyst Edward Tenthoff maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Overweight and lowers the price target from $16 to $7.
benzinga.com Nasdaq Surges 300 Points; Amazon Shares Jump Following Upbeat Earnings US stocks rise, Nasdaq up 300 points. Dow up 0.36%, Nasdaq up 1.31%, S&P 500 up 0.65%. Amazon shares jump 14% after posting strong Q2 results.
benzinga.com This Faeth Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Wall Street analysts changed outlook on top names. Check ratings page for upgrades, downgrades, initiations. See other analysts' views on HTFL, SKYH, FTH.
benzinga.com Amazon To Rally Around 55%? Here Are 10 Top Analyst Forecasts For Friday Analysts change outlook & price targets for Crocs, Monolithic Power, Axos Financial, Amazon, Karyopharm, Apple, Guardant Health, Pagaya Tech.- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-market session. Moleculin Biotech (NASDAQ:MBRX) shares increased by 17.64% to $1.2. The market value of…
benzinga.com This Plexus Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday Top Wall Street analysts upgraded IP, AXTI, REPL, and PLXS stocks with higher price targets. See what other analysts think about these stocks.
benzinga.com This Edison International Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday Wall Street analysts changed outlook on top names. See analyst ratings page for upgrades, downgrades, initiations. Analysts have mixed views on EIX stock.- benzinga.com HC Wainwright & Co. Downgrades Karyopharm Therapeutics to Neutral, Lowers Price Target to $3 HC Wainwright & Co. analyst Robert Burns downgrades Karyopharm Therapeutics (NASDAQ:KPTI) from Buy to Neutral and lowers the price target from $13 to $3.
benzinga.com Why Amazon Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket Amazon reported strong Q2 results, beating revenue and earnings estimates. Shares jumped 11.9% in pre-market trading while other stocks also saw gains/losses.
benzinga.com Karyopharm Stock (KPTI) Crashes After Hours: Here's What's Driving the Move Karyopharm stock plunged after hours after its Phase 3 endometrial cancer trial missed the primary endpoint.